At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET
Skye Bioscience reported Q4 and full-year 2025 financial results, highlighting ongoing clinical progress with its obesity candidate nimacimab, including initiation of a higher-dose expansion study and FDA feedback shaping Phase 2b design. The company emphasized strong combination data with semaglutide, showing 22.3% mean weight loss at 52 weeks and favorable body composition outcomes, but reported a significant net loss increase due to higher R&D and manufacturing costs. Cash runway is expected through Q4 2026, excluding Phase 2b clinical costs.
- Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts to assess safety and pharmacokinetics; topline data expected Q4 2026.
- Received FDA Type C meeting feedback informing Phase 2b combination trial design with incretin therapy.
- Interim 52-week data: 22.3% weight loss with nimacimab + semaglutide, no plateau observed, strong safety profile maintained.
- 13-week off-treatment follow-up: combination cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone; maintained fat loss and gained lean mass.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access